Using Antibody-Drug Conjugates in Later-Line HER2+ Gastric Cancer

home / case-based-roundtable-series / using-antibody-drug-conjugates-in-later-line-her2-gastric-cancer

This roundtable series presents physicians' views on how to treat a patient with locally advanced or metastatic HER2-positive gastric cancer, as discussed by participants at virtual live events.

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Gastric Cancer

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Gastric Cancer

John L. Marshall, MD
March 25th 2022

John Marshall, MD, discusses the DESTINY-Gastric01 study of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

Choosing Second-Line Therapy for HER2+ Gastric Cancer

Choosing Second-Line Therapy for HER2+ Gastric Cancer

Bassel El-Rayes, MD
April 20th 2022

Bassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.

Monitoring AEs of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

Monitoring AEs of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

John L. Marshall, MD
May 9th 2022

John L. Marshall, MD, discusses of the adverse event profile of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

The Role of HER2-Targeted Therapy for Gastric Cancer

The Role of HER2-Targeted Therapy for Gastric Cancer

John L. Marshall, MD
June 17th 2022

John L. Marshall, MD, discusses the situations where patients could benefit from fam-trastuzumab deruxtecan-nxki as second-line treatment for locally advanced or metastatic HER2-positive gastric cancer.